BioGend Therapeutics Co (ROCO:6733) Institutional Ownership: 0.08% (As of Aug. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6733 BioGend Therapeutics Co Ltd ROCO:6733
73 GF Score
Price NT$25.25
GF Value NT$60.16
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is BioGend Therapeutics Co Institutional Ownership?

BioGend Therapeutics Co ROCO:6733 +0.60% 73 Institutional Ownership is 0.08% as of Aug. 16, 2026. GuruFocus rates ROCO:6733 with a GF Score™ of 73/100 and a GF Value™ of NT$60.16 (Significantly Undervalued). The stock has 1 warning sign investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, BioGend Therapeutics Co's institutional ownership is 0.08%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, BioGend Therapeutics Co's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, BioGend Therapeutics Co's Float Percentage Of Total Shares Outstanding is 0.00%.

BioGend Therapeutics Co Institutional Ownership Historical Data

* Premium members only.

The historical data trend for BioGend Therapeutics Co's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioGend Therapeutics Co Institutional Ownership Chart

BioGend Therapeutics Co Historical Data

The historical data trend for BioGend Therapeutics Co can be seen below:

2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31
Institutional Ownership 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08
ROCO:6733
73GF Score
BioGend Therapeutics Co Ltd ROCO:6733
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioGend Therapeutics Co Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 0.08% mean?
BioGend Therapeutics Co (ROCO:6733) has a Institutional Ownership of 0.08% as of Aug. 16, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on BioGend Therapeutics Co and its competitors.
Is BioGend Therapeutics Co's Institutional Ownership too high?
BioGend Therapeutics Co's current Institutional Ownership is 0.08%. Overall, BioGend Therapeutics Co has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioGend Therapeutics Co's Institutional Ownership compare to VRTX and REGN?
BioGend Therapeutics Co's Institutional Ownership of 0.08% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on BioGend Therapeutics Co and its competitors. BioGend Therapeutics Co's current Institutional Ownership is 0.08%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGend Therapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, BioGend Therapeutics Co (ROCO:6733) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$60.16, compared to a current price of NT$25.25 — trading 58% below its estimated fair value. The current Institutional Ownership is 0.08%. BioGend Therapeutics Co's overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For BioGend Therapeutics Co (ROCO:6733), the current Institutional Ownership is 0.08% as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioGend Therapeutics Co (ROCO:6733) Overvalued in 2026?

Based on GuruFocus' analysis, BioGend Therapeutics Co stock appears to be undervalued. The current stock price of NT$25.25 is trading 58% below its estimated GF Value™ of NT$60.16. GuruFocus considers BioGend Therapeutics Co to be Significantly Undervalued.

Key valuation signals for ROCO:6733:

  • Institutional Ownership: 0.08%
  • GF Value™: NT$60.16 vs. price of NT$25.25 (58% below fair value)
  • GF Score™: 73/100 with 1 warning sign

No single metric tells the full story. See the ROCO:6733 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioGend Therapeutics Co Business Description

Address Park Street, 4th Floor, No. 3-2, Nangang District, Taipei, TWN, 115
BioGend Therapeutics Co Ltd is a Taiwan-based company involved in the research and development of orthopedic medical equipment and related products, and the sale of related products. It is involved in the research and development of inventive cartilage repair technology and products, adipose stem cell extraction technology, and others. Geographically, the company generates a majority of its revenue from Taiwan, followed by China, Malaysia, and other regions.
73GF Score

Get the complete analysis for ROCO:6733

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$25.25
Price
NT$60.16
GF Value